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HIF1A (hypoxia-inducible factor 1α) is the master regulator of
the cellular response to hypoxia and is implicated in cancer
progression. Whereas the regulation of HIF1A protein in response
to oxygen is well characterized, less is known about the fate
of HIF1A mRNA. In the present study, we have identified
the pseudo-DUB (deubiquitinating enzyme)/deadenylase USP52
(ubiquitin-specific protease 52)/PAN2 [poly(A) nuclease 2] as an
important regulator of the HIF1A-mediated hypoxic response.
Depletion of USP52 reduced HIF1A mRNA and protein levels
and resulted in reduced expression of HIF1A-regulated hypoxic
targets due to a 3′-UTR (untranslated region)-dependent poly(A)-
tail-length-independent destabilization in HIF1A mRNA. MS
analysis revealed an association of USP52 with several P-body
(processing body) components and we confirmed further that
USP52 protein and HIF1A mRNA co-localized with cytoplasmic
P-bodies. Importantly, P-body dispersal by knockdown of GW182
or LSM1 resulted in a reduction of HIF1A mRNA levels. These
data uncover a novel role for P-bodies in regulating HIF1A mRNA
stability, and demonstrate that USP52 is a key component of
P-bodies required to prevent HIF1A mRNA degradation.
Key words: AU-rich element (ARE)-mediated degradation
(AMD), hypoxia-inducible factor 1α (HIF1A), poly(A) nuclease
2 (PAN2), processing body (P-body), pseudo-deubiquitinating
enzyme (pseudo-DUB), ubiquitin-specific protease 52 (USP52).
INTRODUCTION
Cells respond to reduced oxygen tension by executing a
transcriptional programme that is principally orchestrated by
HIF1A (hypoxia-inducible factor 1α) [1]. HIF1A protein is
synthesized continually, but degraded rapidly by the ubiquitin–
proteasome system under normal oxygen concentrations
(normoxia) [2,3]. This is a result of oxygen-dependent
proline hydroxylation mediated by a family of PHDs
(prolyl hydroxylases). HIF1A containing this hydroxyproline
modification is a substrate for the VHL (von Hippel–Lindau) E3
ubiquitin ligase complex which targets the protein for ubiquitin-
mediated proteolysis [4,5]. Upon decreased oxygen concentration
(hypoxia), such as that observed in solid tumours, HIF1A escapes
proline hydroxylation and degradation to bind its constitutively
expressed partner HIF1B (hypoxia-inducible factor 1β) and
drive the expression of many genes involved in glycolysis,
angiogenesis, cell survival and cancer progression [3].
Whereas the regulation of HIF1A protein is well documented,
little is known about the regulation and turnover of HIF1A mRNA.
The presence of multiple AREs (AU-rich elements) in the 3′-UTR
(untranslated region) of HIF1A and the observation that HuR
binds this 3′-UTR suggested regulation of the HIF1A transcript
via AMD (ARE-mediated degradation) [6]. In support of this, the
presence of AREs in the HIF1A 3′-UTR has been reported to be
necessary for TTP (tristetrapolin)-mediated degradation of HIF1A
mRNA during prolonged hypoxia [7,8]. In addition, the existence
of an aHIF (antisense hypoxia-inducible factor) complementary
to 1027 bases in the HIF1A 3′-UTR has led to the proposal that
HIF1A mRNA is targeted for degradation by binding of aHIF to
its 3′-UTR and exposing AREs to TTP [9]. Indeed, aHIF was
shown to be up-regulated by prolonged hypoxia and correlated
with a reduction in HIF1A mRNA stability [10].
USP52 (ubiquitin-specific protease 52)/PAN2 [poly(A)
nuclease 2] belongs to the ubiquitin-specific protease superfamily,
but exhibits no deubiquitylating activity owing to the lack
of an active-site cysteine residue [11]. It also contains a C-
terminal exonuclease III domain and has been well characterized
in its role as a poly(A) nuclease as part of the PAN2–
PAN3 deadenylation complex [12,13]. PABPC1 [poly(A)-binding
protein C1] recruits the PAN2–PAN3 complex to poly(A) tails
through binding PAN3 and stimulating USP52/PAN2 poly(A)
nuclease activity [14,15]. However, whereas Saccharomyces
cerevisiae USP52/PAN2 deletion mutants accumulate longer
poly(A) tails [12], they are viable because of the CCR4–NOT1
complex providing the major cellular deadenylation activity
[16], and this is also similarly the case in mammalian cells [17].
USP52/PAN2 and PAN3 have also been reported to be
components of cytoplasmic P-bodies (processing bodies) [18].
Interestingly, as PABPC1 is not present in P-bodies, but is required
for USP52/PAN2 nuclease activity, it is likely that USP52/PAN2
has additional functions within P-bodies [18].
In the present study, screening has identified USP52/PAN2 as
an important regulator of the HIF1A-mediated hypoxic response.
Abbreviations used: aHIF, antisense hypoxia-inducible factor; ARE, AU-rich element; AMD, ARE-mediated degradation; CA9, carbonic anhydrase
IX; CHX, cycloheximide; CTNNB1, β-catenin; CUL2, cullin 2; DCP1A, decapping enzyme 1A; DUB, deubiquitinating enzyme; ERG, Ets-related gene;
FBS, fetal bovine serum; FISH, fluorescent in situ hybridization; GFP, green fluorescent protein; GLUT1, glucose transporter 1; HEK, human embryonic
kidney; HIF1A, hypoxia-inducible factor 1α; HIF1B, hypoxia-inducible factor 1β; HRE, hypoxia-response element; LC, liquid chromatography; LDHA,
lactate dehydrogenase A; miRNA, microRNA; MS/MS, tandem MS; NEDD8, neural-precursor-cell-expressed developmentally down-regulated 8; NP-40,
Nonidet P40; NT, Non-Targeting; PABPC1, poly(A)-binding protein C1; PAN2, poly(A) nuclease 2; P-body, processing body; PHD, prolyl hydroxylase; RT,
reverse transcription; siRNA, short interfering RNA; TCE, transcription elongation factor; TRIM21, tripartite motif-containing 21; TTP, tristetrapolin; USP52,
ubiquitin-specific protease 52; UTR, untranslated region; VEGF, vascular endothelial growth factor; VHL, von Hippel–Lindau; YFP, yellow fluorescent
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USP52 was required for HIF1A mRNA stability, and we provide
evidence that this acts through HIF1A’s AU-rich 3′-UTR, but is
independent of poly(A) tail length regulation. Disrupting P-bodies
by GW182 depletion displaces USP52 from P-bodies and reduces
HIF1A mRNA levels. These data thereby reveal USP52 as a key
component of P-bodies required for HIF1A mRNA stability.
EXPERIMENTAL
Cell culture, stable cell generation and DNA transfections
U2OS, HeLa, HEK (human embryonic kidney)-293 and RCC4
cells were maintained in DMEM (Dulbecco’s modified Eagle’s
medium) (Gibco) supplemented with 10% (v/v) FBS (fetal
bovine serum). 786-O cells were maintained in RPMI 1640
medium (Gibco) supplemented with 10% (v/v) FBS. U2OS-
HRE cells [19] were maintained in 0.5 μg/ml puromycin
(Sigma). U2OS-HRE cells stably expressing YFP (yellow
fluorescent protein)–USP52 were generated by transfecting
U2OS-HRE cells with pEFIRES-B-eYFP-USP52 and selecting
with 10 μg/ml blasticidin 48 h after transfection then were
pooled and maintained with 10 μg/ml blasticidin and 0.5 μg/ml
puromycin. Tetracycline-inducible FLAG–USP52 HEK-293 cells
were generated using the T-REx system (Invitrogen) according to
the manufacturer’s instructions and maintained in the presence
of 5 μg/ml blasticidin and 100 μg/ml hygromycin. Induction
was carried out using 1 μg/ml tetracycline. MLN4924 was used
at 3 μM final concentration for 3 h and MG132 treatment was at
20 μM for 4 h. CHX (cycloheximide) (Sigma) treatment was
performed for 2 h at 5 μg/ml and puromycin treatment was for
1 h at 100 μg/ml to modify P-bodies.
Hypoxia treatment
Hypoxia experiments were performed by placing cells under 1%
oxygen in an Invivo2 300 workstation (Ruskinn) for 24 h. Cell
extracts for protein and RNA were taken inside the workstation
to avoid reoxygenation.
Luciferase assays
Luciferase assays were performed by lysing cells in luciferase
buffer [25 mM Tris/phosphate (pH 7.8), 8 mM MgCl2, 1 mM
DTT (dithiothreitol), 1% (w/v) Triton X-100, 15% (v/v)
glycerol, 0.5 mM ATP, 0.5% BSA, 0.125 mM luciferin and
4 μM sodium pyrophosphate] and reading counts on an Envision
2104 plate reader (PerkinElmer). Dual-luciferase assays were
carried out on HEK-293 and U2OS cells co-transfected with
either Renilla luciferase–HIF1A-3′-UTR or Renilla luciferase–
HIF2A-3′-UTR and pcDNA3.1 + -firefly luciferase using the Dual
Luciferase Reporter assay system according to the manufacturer’s
instructions (Promega). Renilla luciferase counts were normalized
to firefly luciferase to control for transfection efficiency. All
luciferase assays were carried out in triplicate and represent at
least two independent experiments.
siRNA (short interfering RNA)
ON-TARGETplus Non-Targeting (NT), USP52, GW182, LSM1
and PAN3 (Dharmacon) siRNAs were used at a final
concentration of 20 nM. siRNA transfections were carried out
using LipofectamineTM RNAi Max (Invitrogen) according to the
manufacturer’s instructions. USP52 and LSM1 siRNA treatments
were for 48 h, GW182 siRNA treatment was for 72 h and PAN3
treatment was for 96 h. Sequences of individual siRNA duplexes
are given in Supplementary Table S1 at http://www.biochemj.org/
bj/451/bj4510185add.htm.
Antibodies and Western blotting
Cells were lysed in NP-40 (Nonidet P40) buffer [50 mM
Hepes/KOH (pH 7.2), 400 mM NaCl, 1% NP-40, 0.2 mM
EDTA and 10% (v/v) glycerol with protease inhibitor cocktail
(Sigma)] and Western blotting was carried out using the following
antibodies: anti-HIF1A (R&D Systems #MAB1536, mouse
monoclonal, 1:1000 dilution) used in Figure 1(A) then anti-HIF1A
(Novus #NB100-134, rabbit polyclonal, 1:1000 dilution) was
used in all subsequent experiments, anti-tubulin (Sigma #T0198,
mouse monoclonal, 1:2000 dilution), anti-USP52 [17] (rabbit
polyclonal, 1:1000 dilution), anti-GFP (green fluorescent protein)
(Roche #11 814 460 001, mouse monoclonal, 1:2000 dilution),
anti-HIF1B (Cell Signaling Technology #5537, rabbit polyclonal,
1:1000 dilution), anti-GLUT1 (glucose transporter 1) (Thermo
Scientific #RB-9052-P, rabbit polyclonal, 1:1000 dilution), anti-
LDHA (lactate dehydrogenase A) (Cell Signaling Technology
#2012, rabbit monoclonal, 1:1000 dilution), anti-CUL2 (cullin
2) (Invitrogen #51-1800, rabbit polyclonal, 1:2000 dilution) and
anti-FLAG (Sigma #F7425, rabbit polyclonal, 1:1000 dilution).
Further methods can be found in the Supplementary Online
Data at http://www.biochemj.org/bj/451/bj4510185add.htm.
RESULTS
USP52/PAN2 is a novel modifier of the hypoxic response
To identify new mediators of the HIF1A-mediated hypoxia
pathway, we used U2OS osteosarcoma cells stably expressing
a firefly luciferase reporter construct fused to three tandem
copies of the iNOS (inducible nitric oxide synthase) HRE
(hypoxia-response element) [19] (Figure 1A). U2OS-HRE cells
responded to hypoxia (1% oxygen) by stabilization of HIF1A
protein and concomitantly displayed an approximately 10-fold
induction of luciferase activity (Figure 1A). The increase in
luciferase activity was largely dependent on HIF1A, as siRNA-
mediated depletion of HIF1A reduced luciferase activity to near-
normoxic levels (Figure 1A). U2OS-HRE cells were screened
with our custom-assembled ‘ubiquitome’ siRNA library targeting
all known and assumed components of the ubiquitin and
ubiquitin-like systems. On this basis, we identified a pool of
siRNAs against USP52 that decrease hypoxia-dependent HRE-
response activity. Deconvolution analysis revealed that two out
of four individual siRNA duplexes targeting USP52 (si1 and si3)
caused over a 40% reduction in luciferase activity, and
this correlated closely with the reduction in USP52 protein by
these siRNAs (Figure 1B). Interestingly, we were only able to
deplete USP52 by approximately 50% as judged by immunoblot
(Figure 1B) and real-time PCR (Supplementary Figure S1A
at http://www.biochemj.org/bj/451/bj4510185add.htm) analysis.
This is consistent with previous reports in mouse NIH 3T3 cells,
where siRNA was reported to reduce USP52 by a maximum of
∼65% compared with control siRNA [17]. USP52 knockdown
specifically impaired the hypoxia response, as it caused no such
impairment to the NF-κB (nuclear factor κB) response after TNFα
(tumour necrosis factor α) stimulation of the HeLa C57A cell line
[20] (Supplementary Figure S1B). Next we generated U2OS-
HRE cell lines stably expressing YFP-tagged USP52 resistant
to either USP52 siRNA si1 or si3 (Figure 1C) and assessed the
ability of siRNA-resistant USP52 to rescue the impaired hypoxic
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Figure 1 USP52 is a regulator of the hypoxia response
(A) U2OS osteosarcoma cells stably expressing a hypoxia reporter construct consisting of three tandem HREs fused to the firefly luciferase gene (U2OS-HRE) were used to identify novel mediators
of the hypoxia response. Western blot analysis demonstrates that HIF1A protein expression increases concomitant with a 10-fold increase in luciferase activity upon hypoxia treatment. Tubulin was
used as a loading control. (B) Deconvolution analysis of USP52 revealed that individual siRNAs si1 and si3 both elicited an impaired response to hypoxia that correlated with the ability of these
oligonucleotides to reduce USP52 protein levels by approximately 50 %. Tubulin was used as a loading control. (C) Western blot of U2OS-HRE cells stably expressing siRNA-resistant YFP–USP52
were resistant to the individual siRNA as indicated, but remained sensitive to the other siRNA. (D) Luciferase assays of siRNA-resistant cells lines revealed USP52 si1 treatment was rescued to 80 %,
whereas si3 treatment was rescued to 95 %. Cell lines remained sensitive to the individual siRNA to which resistance was not designed. Molecular masses are indicated in kDa in the blots, and
results in histograms are means +− S.E.M.
response upon endogenous USP52 knockdown. Hypoxia-induced
luciferase activity was rescued to approximately 80% and 95%
in si1- and si3-resistant cells respectively, thus validating USP52
as a novel activator of the HIF1A-mediated hypoxic response
(Figure 1D).
USP52 potentiates the hypoxic response
To investigate further the role of USP52 in the HIF1A-mediated
hypoxic response, U2OS cells were treated with individual
USP52 siRNA duplexes 1 and 3 and exposed to hypoxia.
Knockdown of USP52 correlated with a specific decrease in
HIF1A, but not HIF1B, protein levels (Figure 2A), suggesting that
decreased HIF1A protein is responsible for the impaired hypoxia
response. GLUT1 and LDHA are both hypoxia-responsive genes
which accumulate in U2OS cells in a HIF1A-dependent manner
(Supplementary Figure S1C). Examination of GLUT1 and LDHA
levels by immunoblot analysis of hypoxic U2OS cells revealed
that USP52 depletion impairs the accumulation of GLUT1 and
LDHA in response to hypoxia (Figure 2A), thus demonstrating
that USP52 is required to potentiate the HIF1A-mediated hypoxic
response. Similar results were obtained in mouse cells, indicating
that USP52 has a conserved role in the hypoxia response (results
not shown). Furthermore, real-time RT (reverse transcription)–
PCR analysis from USP52-depleted U2OS cells demonstrated
that the accumulation of the HIF1A target genes CA9 (carbonic
anhydrase IX), PHD2 and VEGF (vascular endothelial growth
factor) in response to hypoxia were all reduced (Figure 2B),
confirming the role of USP52 in the HIF1A pathway. Interestingly,
it has been reported previously that USP52/KIAA0710 mRNA
itself was induced 3.1-fold in response to hypoxia determined
by microarray analysis of human renal cancer 786-O cells [21].
Whereas examination of the USP52 promoter region revealed the
presence of an HRE consensus motif (RCGTG) (Supplementary
Figure S1D), no hypoxic increase in USP52 protein was detected
in either 786-O or RCC4 cells (Supplementary Figure S1D), or in
U2OS cells, HeLa cells or MEFs (mouse embryonic fibroblasts)
(results not shown).
USP52 regulates HIF1A mRNA
To gain insight into how USP52 may alter HIF1A protein
levels, we performed protein network analysis of known USP52-
interacting partners (Supplementary Figure S2A at http://www.
biochemj.org/bj/451/bj4510185add.htm). Interestingly, USP52
was reported previously to immunoprecipitate TCE (transcription
elongation factor) B1/elongin C and TCEB2/elongin B [22],
which constitute part of the VHL E3 ligase complex required
for the bulk of HIF1A degradation. The VHL complex is a
cullin-type E3 ligase which requires CUL2 NEDD8ylation for
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Figure 2 USP52 potentiates the hypoxic response
(A) Depletion of USP52 using siRNA si1 or si3 in U2OS cells reduces the levels of HIF1A, but not HIF1B, protein as assessed by Western blot analysis. HIF1A transcriptional targets GLUT1 and
LDHA also showed decreased protein expression. Tubulin was used as a loading control. Molecular masses are indicated in kDa. (B) Real-time RT–PCR analysis shows that the expression of HIF1A
targets CA9, PHD2 and VEGF are all induced in U2OS cells in response to hypoxia. USP52 knockdown reduces the ability of cells to increase expression of all HIF1A target genes. Levels were
normalized to β-actin. Results are means +− S.E.M.
ligase activity. To address whether USP52 negatively regulates
HIF1A protein through interactions with the VHL complex,
U2OS cells were treated with MLN4924 [23] to inhibit the
NEDD8 (neural-precursor-cell-expressed developmentally down-
regulated 8)-interacting enzyme and block VHL activity. Non-
ubiquitylated HIF1A accumulated in normoxia upon MLN4924
treatment concomitant with the blockage of CUL2 NEDD8ylation
(Figure 3A). However, depletion of USP52 caused a reduction in
HIF1A protein even in the presence of MLN4924, suggesting
that USP52 affects the HIF1A pathway independently of the
VHL complex (Figure 3A). RCC4 cells lack functional VHL and
therefore constitutively express HIF1A in normoxia [4]. In support
of a VHL-independent role of USP52 in the HIF1A pathway,
knockdown of USP52 in RCC4 cells caused a subsequent decrease
in HIF1A levels (Figure 3B). In addition to VHL, several other
proteins have been reported to be involved in targeting HIF1A for
proteasomal degradation, such as RACK1 (receptor for activated
C-kinase 1) [24], HAF (hypoxia-associated factor) [25] and
CHIP [C-terminus of the Hsc (heat-shock cognate) 70-interacting
protein] [26]. In order to exclude USP52 knockdown promoting
HIF1A depletion through alternative degradation pathways,
U2OS cells depleted of USP52 were treated with the proteasome
inhibitor MG132. Proteasome inhibition caused the accumulation
of ubiquitylated HIF1A (Supplementary Figure S2B) in NT
siRNA-treated, but not USP52-depleted, cells, confirming that
regulation of HIF1A by USP52 does not occur at the level
of proteasomal degradation (Supplementary Figure S2B). To
determine whether USP52 knockdown alters HIF1A mRNA
levels, real-time RT–PCR was performed on cDNA prepared from
U2OS cells. USP52 depletion caused an approximately 60%
reduction in the abundance of HIF1A mRNA (Figure 3C). As
a control, HIF1A siRNA depleted HIF1A mRNA by over 90%
(Figure 3C). To assess whether depletion of USP52 also affected
HIF2A mRNA steady-state levels, HeLa cells were used as they
express higher levels of HIF2A than U2OS cells. Whereas USP52
depletion caused a comparable reduction in HIF1A mRNA in
HeLa cells, the levels of HIF2A actually increased approximately
2-fold (Figure 3D). This demonstrates that USP52 knockdown
specifically reduces HIF1A mRNA abundance, and supports the
previous observation that decreased HIF1A mRNA is associated
with up-regulation of HIF2A [19]. We also assessed the effect
of USP52 depletion on mRNA levels of the unrelated genes
ERG (Ets-related gene) and CTNNB1 (β-catenin). Transcript
levels of both ERG and CTNNB1 were increased ∼1.5-fold upon
USP52 depletion (Figure 3D), consistent with the expected role
of USP52 in mRNA degradation-dependent deadenylation. These
results show that the role of USP52 in maintaining HIF1A mRNA
levels displays a certain level of specificity.
USP52 is required for HIF1A mRNA stability
USP52 depletion could modify the steady-state levels of
HIF1A mRNA through modulating its transcription or stability.
To distinguish between these possibilities, we performed
actinomycin D chase experiments to measure the half-life of
HIF1A mRNA after USP52 knockdown. Actinomycin D inhibits
RNA polymerase II to block transcription and therefore allows
measurement of mRNA decay. Depletion of USP52 in U2OS
cells dramatically enhanced the degradation of HIF1A mRNA
(Figure 4A), where the half-life of HIF1A in NT-treated cells was
214 min (Supplementary Figure S3A at http://www.biochemj.
org/bj/451/bj4510185add.htm) and reduced to 35 min upon
USP52 depletion (Supplementary Figure S3B). In order to
determine whether the effect of USP52 depletion on HIF1A
mRNA stability was associated with a change in HIF1A poly(A)
tail length, we analysed poly(A) tail length in U2OS cells
treated with NT or USP52 siRNA. Surprisingly, there was no
apparent difference in the length of the HIF1A poly(A) tail
after USP52 depletion, indicating that USP52 stabilizes HIF1A
mRNA in a poly(A)-tail-length-independent manner (Figure 4B).
The presence of multiple AREs in HIF1A’s 3′-UTR results in
the regulation of HIF1A by AMD [7,8]. To determine whether
USP52 regulates HIF1A stability through stabilizing its 3′-
UTR, we used a Renilla luciferase reporter construct fused to
the HIF1A 3′-UTR. Depletion of USP52 in HEK-293 cells
inhibited HIF1A 3′-UTR activity by approximately 50%
(Figure 4B), supporting a role for USP52 in HIF1A stabilization
by preventing its AMD. Similar results were obtained upon
USP52 knockdown in U2OS cells (Supplementary Figure S3C).
Interestingly, USP52 knockdown resulted in an increase in the
levels of HIF2A Renilla 3′-UTR in HEK-293 cells (Figure 4C),
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Figure 3 USP52 regulates the hypoxia pathway in a VHL-independent manner by controlling HIF1A mRNA levels
(A) Normoxic U2OS cells were treated with MLN4924 to block CUL2 NEDD8ylation and inactivate the VHL complex. USP52 depletion was sufficient to decrease HIF1A protein levels, demonstrating
independence of the VHL complex. Tubulin was used as a loading control. (B) USP52 depletion in VHL-deficient RCC4 renal cancer cells reduced HIF1A protein levels under normoxia. Tubulin was
used as a loading control. (C) U2OS cells were treated with siRNA against USP52 and HIF1A , and the levels of HIF1A mRNA were assessed by real-time RT–PCR analysis. HIF1A siRNA reduced
HIF1A mRNA levels to below 10 %, whereas USP52 depletion reduced HIF1A mRNA to approximately 40 %. Levels were normalized to β-actin. (D) USP52 was depleted in HeLa cells which were
subject to real-time RT–PCR analysis. HIF1A mRNA levels were reduced by approximately 50 % in HeLa cells by USP52 knockdown. HIF2A levels were increased 2-fold upon USP52 knockdown,
whereas ERG and CTNNB1 mRNA levels were both increased 1.5-fold upon USP52 depletion. Levels were normalized to β-actin. Molecular masses are indicated in kDa in the blots, and results in
histograms are means +− S.E.M.
suggesting that the observed antagonism between HIF1A and
HIF2A levels [19] (Figure 3D) may be regulated in a manner
depending on the HIF2A 3′-UTR. To rule out any effects of USP52
on HIF1A translation, we performed polysome profiling on U2OS
cells treated with either NT or USP52 siRNA. There were no clear
differences in the distribution of HIF1A mRNA between the non-
translating and translating fractions (Supplementary Figure S4 at
http://www.biochemj.org/bj/451/bj4510185add.htm), suggesting
the effects of USP52 depletion are not mediated at the translation
level. Collectively, these results demonstrate that USP52 regulates
HIF1A mRNA stability in a 3′-UTR-dependent but poly(A)-tail-
length-independent manner.
USP52 is a component of cytoplasmic P-bodies
To obtain insight into the observed USP52-mediated stabilization
of HIF1A mRNA, we performed proteomic analysis of USP52
immunoprecipitates to identify new USP52-associated proteins.
HEK-293 cells which stably express FLAG-tagged USP52
in a tetracycline-responsive manner were generated (Fig-
ure 5A). FLAG–USP52 expression was induced for 24 h before
anti-FLAG-conjugated beads were used to immunoprecipitate
FLAG–USP52 complexes. Immunoprecipitated material from
induced and uninduced control cells was separated by denaturing
gel electrophoresis and silver-stained to reveal the presence of
specific USP52-associated proteins of various sizes (Figure 5B).
The remaining material was subject to in-solution tryptic digestion
and LC (liquid chromatography)–MS/MS (tandem MS) analysis
to identify interacting proteins (Figure 5B). The full dataset is
listed in Supplementary Table S4 at http://www.biochemj.org/
bj/451/bj4510185add.htm. We were interested by the identifica-
tion of the P-body components TRIM21 (tripartite motif-
containing 21), PCBP1 and PAN3 in USP52 immunoprecipitates
(Supplementary Table S4), given the role of P-bodies in mRNA
storage and/or degradation [27]. To confirm that USP52 is a
component of P-bodies [18], immunostaining of U2OS cells with
antibodies against USP52 and the essential P-body component
GW182 demonstrated that USP52 co-localizes to P-bodies
(Figure 5D). Quantification revealed that 92.5% of GW182
P-bodies were also USP52-positive (Figure 5D). Treatment
of cells with CHX or puromycin is known to abolish or
increase respectively the number of P-bodies [27]. We confirmed
that USP52 P-body foci were likewise abolished by CHX
treatment, while the number increased upon puromycin treatment
(Supplementary Figure S5A at http://www.biochemj.org/bj/451/
bj4510185add.htm). This confirmed that USP52 is a genuine
P-body component and raised the possibility that USP52 may
serve a role in regulating HIF1A mRNA through its association
with P-bodies.
Disrupting USP52-containing P-bodies by GW182 depletion
reduces HIF1A mRNA
The co-localization of USP52 with P-bodies led us to hypothesize
that P-bodies might be important for HIF1A mRNA stability.
GW182 is essential for P-body integrity, as its depletion abolishes
the presence of visible P-bodies [28]. To determine whether
P-body disruption correlated with changes in HIF1A mRNA
levels, we depleted GW182 from U2OS cells. GW182
siRNA caused a decrease in the proportion of cells containing
P-bodies, whereas any remaining P-bodies were visibly smaller
(Figure 6A). USP52 foci were dispersed upon GW182 depletion,
confirming that the presence of USP52-positive P-bodies is
dependent on GW182 (Figure 6A) and quantification of P-bodies
revealed that the percentage of cells containing at least one P-body
decreased from 80% in NT siRNA-treated cells to approximately
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Figure 4 USP52 is required for stability of HIF1A mRNA
(A) Actinomycin D (ACT-D) chase experiments were performed in U2OS cells treated with either NT or USP52 siRNA. Real-time RT–PCR analysis revealed that depletion of USP52 decreased HIF1A
mRNA half-life from 214 min to 35 min. Initial mRNA levels were normalized to 100 % to account for lower HIF1A levels in USP52-depleted cells. Levels were normalized to β-actin. (B) U2OS cells
were treated with NT or USP52 siRNA, and cDNA was made from G/I-tailed mRNA. PCR was performed using primers within HIF1A 3′-UTR (a + b) to generate a 221 bp product, and in a separate
reaction with forward primer (a) and universal reverse primer (c). Poly(A) tail length in both NT and USP52 siRNA-treated cells was found to be predominantly ∼60 residues long, calculated by
subtracting the size of the (a + b) reaction product from the size of the (a + c) reaction product. Sizes are indicated in bp. (C) HEK-293 cells depleted of USP52 were transfected with the HIF1A
3′-UTR Renilla luciferase reporter shown. USP52 knockdown caused a 50 % decrease in the expression of HIF1A 3′-UTR construct. Renilla luciferase values were normalized to firefly luciferase to
control for transfection efficiency. (D) HEK-293 cells depleted of USP52 were transfected with the HIF2A 3′-UTR Renilla luciferase reporter shown. HIF2A 3′-UTR expression was increased 2-fold
upon USP52 depletion. Renilla luciferase values were normalized to firefly luciferase to control for transfection efficiency. Results are means +− S.E.M.
20% in GW182 siRNA-treated cells (Supplementary Figure 5B).
Importantly, we observed a reduction in HIF1A mRNA levels of
almost 80% upon GW182 depletion (Figure 6B), suggesting that
P-body integrity plays an important role in maintaining HIF1A
mRNA levels. Whereas GW182 depletion dispersed USP52-
positive P-bodies, it had no effect on steady-state levels of USP52
protein, suggesting that HIF1A mRNA levels were not affected
by simply reducing the amount of USP52 protein (Supplementary
Figure S5C). As GW182 has also been proposed to be involved
in regulating the miRNA (microRNA) pathway, it was important
to confirm that dispersing P-bodies by depleting another P-body
component independent of the miRNA pathway had the same
effect on HIF1A mRNA. We therefore depleted LSM1, which
dispersed P-bodies (Supplementary Figure S5C) while also
resulting in a reduction of HIF1A mRNA to approximately 20%
(Figure 6C). PAN3 has been shown to recruit USP52 to P-bodies,
and its depletion was also shown to reduce P-body number as
well as destabilize AMD substrates [18]. We therefore depleted
PAN3 in U2OS cells and observed that HIF1A mRNA levels
were decreased to 60% compared with NT siRNA (Figure 6D).
Altogether, these results suggest that P-bodies are important
regulators of steady-state HIF1A mRNA levels, and that USP52 is
a key component of P-bodies required for HIF1A mRNA stability.
HIF1A mRNA is present in P-bodies
The finding that USP52 is a P-body component required for
HIF1A mRNA stability coupled to our finding that reducing
the number of cellular P-bodies depletes HIF1A mRNA raised the
possibility that HIF1A mRNA might be present within P-
bodies. To test this directly, we performed FISH (fluorescent in
situ hybridization) with antisense Texas-Red-X-labelled probes
specific to HIF1A mRNA on U2OS cells transfected with
the P-body marker GFP–DCP1A (decapping enzyme 1A). A
GFP-tagged P-body marker was used to circumvent problems
associated with the destruction of endogenous epitopes upon harsh
denaturing conditions required for FISH. HIF1A antisense probes
formed discrete cytoplasmic foci which co-localized with GFP–
DCP1A-positive P-bodies (Figure 7A), suggesting that HIF1A
mRNA is a P-body constituent. Non-specific fluorescence was
deduced by using HIF1A sense control probes, which did not show
an obvious co-localization with GFP–DCP1A (Figure 7A). The
proportion of GFP–DCP1A P-bodies co-localizing with HIF1A
antisense probes was calculated to be 52%, whereas antisense
probes showed a 10% co-localization rate (Figure 7B), probably
due to background fluorescence showing coincidental overlap
with GFP–DCP1A. Therefore a proportion of HIF1A mRNA is
found within P-bodies, suggesting that these may act as storage
sites for HIF1A mRNA.
DISCUSSION
HIF1A is the master regulator of the cellular response to
hypoxia which is responsible for executing a transcriptional
programme endowing cells with the capacity to deal with hypoxic
stress [3]. Whereas the oxygen-dependent regulation of HIF1A
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Figure 5 USP52 interacts with P-body components
(A) HEK-293 cells expressing tetracycline (TETc)-inducible FLAG–USP52 were generated. USP52 expression was induced by 16 or 40 h of TETc treatment as assessed by Western blot analysis.
Tubulin was used as a loading control. (B) Inducible USP52 cells were either untreated or treated with TETc before FLAG–USP52 immunopreciptation. A fraction of eluted proteins (1/20th) were
separated by denaturing gel electrophoresis and silver-stained. The position of FLAG–USP52 is indicated by an arrow. The remaining volume of eluted proteins was prepared for LC–MS/MS analysis
as indicated in the flow chart. (C) Co-immunofluorescent staining of U2OS cells with USP52 and the P-body marker GW182 confirms that USP52 is a component of P-bodies. Quantification revealed
that over 90 % of P-bodies were USP52-positive, where 468 P-bodies were counted from 113 cells. Scale bars, 30 μm. Cells were counterstained with DAPI (4′,6-diamidino-2-phenylindole).
Molecular masses are indicated in kDa in the blots.
protein has been well described, it is becoming increasingly
apparent that regulation of HIF1A mRNA also plays an important
role in regulating HIF1A-dependent processes. In the present
study, we have identified the P-body component USP52/PAN2
as an important stability factor for HIF1A mRNA, and have
demonstrated that it prevents degradation of HIF1A mRNA in a
3′-UTR-dependent, but poly(A)-tail-length-independent, manner.
P-bodies are dynamic structures which are important in
both mRNA decay and miRNA-mediated translational silencing,
acting as a store for mRNAs before their release back into active
polysomes [27]. It is clear that miRNA pathways are important
regulators of the hypoxic response and that several miRNAs are
up-regulated in response to hypoxia [29]. In addition, a Drosophila
genome-wide siRNA screen identified several components of the
miRNA machinery that were required for a complete hypoxic
response, including the P-body components Ago1 and GW182
[30]. The fact that P-bodies are reported to be a site of ARE-
containing mRNA storage and AMD [31] suggested that HIF1A
mRNA may be stored and/or degraded in P-bodies. Our finding
that depletion of the P-body component USP52 destabilizes
HIF1A mRNA via its AU-rich 3′-UTR suggests that USP52 plays
a key role in preventing AMD of HIF1A mRNA in P-bodies. This
may occur through preventing the association of HIF1A 3′-UTR
with AMD-promoting proteins such as TTP, which is present in
P-bodies and known to promote the degradation of ARE-
containing mRNAs including HIF1A [7,8,31]. Although we
cannot rule out the possibility of indirect effects of USP52 on
HIF1A mRNA stability, our finding that HIF1A mRNA and
USP52 protein both reside in P-bodies coupled with the fact that
abolishing visible P-bodies also destabilizes HIF1A mRNA sup-
ports a more direct role for USP52 in regulating HIF1A mRNA.
Deadenylation of mRNA occurs through the concerted actions
of the PAN2–PAN3 and CCR4–CAF1 complexes [17], and is a
necessary first step in all major mRNA decay pathways including
AMD and miRMD (miRNA-mediated decay) [32]. Although
USP52/PAN2 is dispensable in yeast [12], consistent with the
fact that CCR4 provides the major cellular deadenylation activity
[16], our finding that USP52 is required for HIF1A mRNA
stability was surprising. However, this apparent paradox may be
explained by USP52 playing additional roles to deadenylation
when localized in P-bodies, which is supported by the finding
that PABPC1 (which is required for USP52 nuclease activity) is
absent from P-bodies [18,33]. Indeed, we did not observe any
effect of USP52 depletion on the length of the HIF1A poly(A)
tail (Figure 4B), and it is consistent with our finding that, whereas
USP52 depletion destabilized HIF1A mRNA, overexpression of
a nuclease-dead USP52 was as efficient as wild-type USP52
in enhancing the HIF1A-mediated hypoxic response (results
not shown). Interestingly, it has also been reported that PAN3
depletion causes a reduction in P-body number concomitant with a
destabilization of ARE-containing transcripts [18]. Furthermore,
these authors showed that PAN3 was able to recruit USP52/PAN2
to P-bodies [18]. It is therefore a possibility that PAN3 depletion
prevents USP52 localization to P-bodies and thus contributes to
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Figure 6 GW182 maintains P-body integrity and HIF1A mRNA levels
(A) U2OS cells treated with either NT or GW182 siRNA were co-immunostained with USP52 and GW182. GW182 depletion by siRNA reduced the total number of P-bodies and dispersed USP52
from foci. Scale bars, 30 μm. Cells were counterstained with DAPI (4′,6-diamidino-2-phenylindole). (B) GW182 depletion caused a reduction in HIF1A mRNA levels to approximately 20 %. Levels
were normalized to β-actin. (C) LSM1 depletion caused a reduction in HIF1A mRNA levels. (D) PAN3 depletion caused a reduction in HIF1A mRNA levels. Levels were normalized to β-actin. Results
in histograms are means +− S.E.M.
Figure 7 HIF1A mRNA localizes to P-bodies
(A) U2OS cells were transfected with GFP–DCP1A, and HIF1A mRNA localization was assessed by FISH analysis with Texas-Red-X-labelled antisense probes. HIF1A was found to
co-localize to GFP–DCP1A-positive P-bodies, whereas only background co-localization was observed with sense control probes. Scale bars, 30 μm. Nuclei were counterstained with DAPI
(4′ ,6-diamidino-2-phenylindole). (B) The number of GFP–DCP1A-positive P-bodies containing HIF1A fluorescence (n = 284) compared with sense control (n = 489) were determined.
the destabilization of AMD substrates, as we have observed in the
case of HIF1A. In this scenario, USP52 may regulate the stability
of other ARE-containing transcripts in addition to HIF1A.
USP52 has also been implicated in miRNA pathways, as it
was shown to be recruited by GW182 through interactions with
PAN3 in humans, Drosophila and Caenhorhabditis elegans [34–
37]. It is therefore possible that GW182 recruits USP52 to
P-bodies through interactions with PAN3 [18]. We observed
that P-body dispersal correlates with decreased levels of HIF1A
mRNA, suggesting that the degradation of HIF1A mRNA
is prevented by USP52 within P-bodies. This is consistent
with previous observations that ARE-containing transcripts are
recruited to and stored in P-bodies [31], and we confirm further
that HIF1A mRNA is present within P-bodies [38,39]. In addition,
it was shown that genetic disruption of GW182 in Drosophila
dramatically reduced the mRNA levels of the HIF1A homologue
Sima in response to hypoxia [30], suggesting that there is a highly
conserved role for P-bodies in maintaining HIF1A mRNA levels.
USP52 exhibits homology with the ubiquitin-specific protease
family, but is not an active DUB (deubiquitinating enzyme) owing
to mutations in two of the three residues of the catalytic triad
[11]. We therefore were initially interested in the possible role
of USP52 as a pseudo-DUB. Pseudo-DUBs may be predicted
to act in a dominant-negative manner preventing other DUBs
from gaining access to their substrate, or alternatively they
may bind ubiquitylated proteins and play a scaffolding role in
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protein–protein interactions. Interestingly, we found several
peptides corresponding to ubiquitin in our USP52 immuno-
precipitates, and transiently overexpressing USP52 harbouring
a Cys-box deletion mutation in the UCH (ubiquitin C-terminal
hydrolase) domain resulted in a decrease in HIF1A protein
(results not shown), suggesting that this domain may be important
in protecting HIF1A mRNA in P-bodies. Interestingly, it has
recently been reported that the RNA-binding E3 ubiquitin ligase
MEX-3C is required for the RING-dependent 3′-UTR-mediated
degradation of HLA-A2 mRNA, suggesting that there is a wider-
role for ubiquitin-handling proteins in mRNA stability pathways
[40]. Intriguingly, we identified the E3 ubiquitin ligase and P-body
component TRIM21 as a USP52-associated protein, opening the
possibility that USP52 may be involved in regulating the function
of TRIM21 or its substrates. Future studies exploring the potential
role of USP52 as a pseudo-DUB in its role in P-body function will
be useful in expanding the understanding of ubiquitin-mediated
regulation of RNA metabolism.
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EXPERIMENTAL
Plasmids
The Renilla luciferase–HIF1A-3′-UTR and Renilla luciferase–
HIF2A-3′-UTR plasmids were purchased from Switchgear
Genomics. Plasmid pcDNA5-FRT/TO-FLAG-USP52 was made
by amplifying USP52 isoform 3 from a human cDNA library (with
primers forward 5′-GCGGCCGCCATGAACTTTGAGGGT-3′
and reverse 5′-GCGGCCGCTCAGAGCGCCAGCACT-3′) and
using standard cloning techniques. The pEFIRES-B-eYFP vector
was created by inserting the eYFP (enhanced YFP) sequence
from pEYFP-C1 (Clontech) into the multiple cloning site of
pEFIRES-P [37] and replacing the puromycin selection marker
with a blasticidin resistance marker. The pEFIRES-B-eYFP-
USP52 plasmid was generated by PCR amplification of USP52
(isoform 1) from an IMAGE clone (with primers forward 5′- GT-
AGATCTATGAACTTTGAGGGTCTGGACC-3′ and reverse 5′-
GTGCGGCCGCTCAGAGCGCCAGCACTGAGGAG-3′) and
using standard cloning techniques. YFP–USP52 siRNA-resistant
forms were generated by standard mutagenesis protocols to
make silent mutations (si1-resistant mutant g1545a; t1548c;
t1551c and si3-resistant mutant g2634a; c2640a; t2643c).
pcDNA5-FRT/TO-GFP-DCP1A was generated by amplifying
DCP1A from IMAGE clone (3029175) with primers (forward 5′-
GGGGCGGCCGCGATGGAGGCGCTGAGTCGAGCTGGG-
3′ and reverse 5′- GGGGCGGCCGCTCATAGGTTGTGGTTGT-
CTTTGTT-3′) and using standard cloning techniques. All DNA
transfections were carried out with LipofectamineTM 2000
according to the manufacturer’s instructions.
RNA, real-time RT–PCR and poly(A) tail length analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and
cDNA synthesis was performed with First Strand cDNA synthesis
kit (Fermentas) according to the manufacturer’s instructions.
USP52 real-time assays were performed using PerfeCtaTM SYBR
Green fast mix (Quanta Biosciences) at 95 ◦C for 10 min, and 45
cycles of 15 s at 95 ◦C and 1 min at 58 ◦C. All other real-time RT–
PCR was performed using probe-based Solaris assays (Thermo
Scientific) using the manufacturer’s recommended reactions and
cycling conditions. All of the assays used gave standard curves
giving between 90 and 105% efficiency and R2 values of
0.99, and were performed on a Bio-Rad CFX96 real-time system
and analysed using CFX Manager software version 1.5 (Bio-
Rad Laboratories). All assays were performed with biological
triplicates and technical duplicates. Primer and probe sequences
are given in Table S2. Actinomycin D chase experiments were
performed by treating cells with 1 μg/ml actinomycin D (Sigma)
for the indicated time after 48 h of siRNA treatment. Values
were normalized to 100% in untreated cells and the percentage
remaining was calculated after actinomycin D treatment. Poly(A)
tail length was calculated using the Poly(A) Tail Length Assay
Kit (Affymetrix). Total RNA was harvested from U2OS cells
treated with either NT or USP52 siRNA, poly(A) tails were G/I-
tailed and converted into cDNA according to the manufacturer’s
instructions. Forward and reverse primers were designed in the
HIF1A 3′-UTR (5′-TTATGCACTTTGTCGCTATTAAC-3′ and
5′-GCCTGGTCCACAGAAGATG-3′ respectively) to generate a
221 bp product. Forward primer and the supplied universal reverse
primer were then used to generate a product whose size was 221 bp
plus the poly(A) tail length, thus allowing calculation of poly(A)
tail length. Products were analysed on a 2.5% agarose gel.
IP (immunoprecipitation) and MS
For IP experiments, induced and uninduced T-REx FLAG–
USP52 cells were lysed in IP buffer [50 mM Tris/HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1% (w/v) Triton X-100 and
protease inhibitor cocktail (Sigma)] and anti-FLAG M2 affinity
gel (Sigma, #A2220) was used to precipitate FLAG-tagged
USP52 according to the manufacturer’s instructions. Beads were
washed five times with IP buffer, then a further five times with
IP buffer lacking detergent. Proteins were sequentially eluted
with 0.2 M glycine (pH 2.5) then 8 M urea (pH 8) and buffered
in 10 mM ammonium bicarbonate. Eluates were reduced with
5 mM TCEP [tris-(2-carboxyethyl)phosphine] (45 min at 37 ◦C),
alkylated with 15 mM iodacetamide [45 min at room temperature
(20 ◦C)] and digested with trypsin overnight at 37 ◦C. Peptides
were acidified to pH <3.0 with TFA (trifluoroacetic acid) and
purified on C18 microspin columns (Nest Group) before MS
analysis. Samples were analysed by LC–MS/MS on an LTQ
Orbitrap Velos instrument (Thermo Fisher Scientific). Data were
analysed using Mascot (http://www.matrixscience.com). Peptides
found in control only cells were assumed to be non-specific
contaminants and disregarded.
Immunofluorescence, FISH and deconvolution microscopy
Immunofluorescent labelling was carried out on U2OS cells
grown on Lab-Tek® chamber slides (Nunc). Cells were fixed
with 5% (w/v) formaldehyde for 10 min and permeabilized
with methanol for 5 min before blocking in DMEM (Dulbecco’s
modified Eagle’s medium) containing 10% (w/v) FBS for
1 h. Primary and secondary antibodies were diluted in block,
and incubations were carried out for 1 h each. Secondary
antibodies were Cy5 (indodicarbocyanine)-conjugated IgG from
Jackson ImmunoResearch Laboratories, and Alexa Fluor® 488-
conjugated IgG from Invitrogen. Cells were counterstained
with DAPI (4′,6-diamidino-2-phenylindole) (Sigma) for 10 min,
mounted in Fluorescent Mounting Medium (Dako) and
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Figure S1 USP52 and hypoxia
(A) USP52 siRNA reduces the level of USP52 mRNA to approximately 50 % that by NT siRNA
in U2OS cells. Levels were normalized to β-actin. (B) HeLa cells expressing an NF-κB (nuclear
factor κB)-dependent luciferase promoter were stimulated with TNFα (tumour necrosis factor
α) in duplicate. USP52 depletion did not cause impairment in the NF-κB-dependent response
to TNFα stimulation. (C) Immunoblot analysis demonstrates that GLUT1 and LDHA are both
up-regulated in U2OS cells in a HIF1A-dependent manner upon exposure to 24 h of hypoxia.
(D) USP52 contains an HRE in its regulatory region. USP52 is not induced by hypoxia in 786-O
or RCC4 renal cancer cells. Molecular masses are indicated in kDa in the blots, and results in
histograms are means+−S.E.M.
coverslipped. Primary antibodies used were anti-USP52 [28]
(rabbit polyclonal, 1:1000 dilution) and anti-GW182 (human
autoantigen, 1:6000 dilution). Stained cells were viewed on
a Delta Vision DV3 deconvolution microscope with an oil-
immersion ×40 or ×63 objective lens and images were
processed using Softworx (Applied Precision). Images presented
are maximal intensity projections from deconvolved three-
dimensional images. The proportion of GW182 P-bodies also
containing USP52 was calculated by counting 468 P-bodies from
113 cells in deconvolved image projections of each field. The
percentage of P-bodies per cell in NT or GW182 siRNA-treated
cells was calculated by counting the proportion of cells containing
at least one P-body. At least 185 cells were counted for each
condition. For FISH experiments, U2OS cells were transfected
with GFP–DCP1A for 24 h, then fixed in 5% formaldehyde for
10 min. Cells were permeabilized in 70% ethanol overnight then
rehydrated in 50% formamide and 2× SSC (0.3 M NaCl/0.03 M
sodium citrate) for 10 min. Next antisense or control sense Texas-
Red-X (Invitrogen)-labelled probes (sequences given in Table S3)
were diluted at 10 ng/μl in hybridization buffer (50% formamide,
2× SSC, 2 mM vanadyl ribonucleoside complexes, 100 μg/ml
total yeast RNA, 0.02% BSA and 0.1 mg/ml dextran sulfate)
and cells were incubated with diluted probes in a humid 37 ◦C
chamber overnight. Cells were washed in 50% formamide and
2× SSC twice for 30 min each before counterstaining with DAPI
and coverslipping. Microscopy was as described above and at
least 280 P-bodies per condition (antisense and sense) of projected
deconvolved images carried out were counted.
Figure S2 USP52 regulates HIF1A independently of proteasomal
degradation
(A) Ingenuity Pathway Analysis was employed to reveal USP52-interacting proteins and
regulators, including TCEB2/elongin B and TCEB1/elongin C. (B) U2OS cells treated with
USP52 siRNA were exposed to 24 h of hypoxia and treated with the proteasome inhibitor
MG132. HIF1A protein levels were not rescued upon proteasome inhibition, demonstrating
that USP52 does not alter HIF1A protein catabolism. Tubulin was used as a loading control.
Molecular masses are indicated in kDa.
Table S1 Sequence of siRNAs
siRNA Sequence (5′→3′)
USP52 (si1) GACCUUGUUUGCUGGAUUA
USP52 (si2) UCAAGGGUCUUUAUGAGAA
USP52 (si3) GCAAGGAGGGCGUUACUCA
USP52 (si4) AAGAACAACCUCAAGUAUA
GW182 (si1) GCCUAAAUAUUGGUGAUUA
GW182 (si2) GAACAAACUGCCUAGCAAU
GW182 (si3) CAGUUUAUGUCCAGUCAAA
GW182 (si4) CCGGCJUCAGUGCAGAAUA
LSM1 (si1) CGAGAUGGAAGGACACUUA
LSM1 (si2) GCGUAUUCAUGUGGGCAAA
LSM1 (si3) GCAAGUAUCCAUUGAAGAA
LSM1 (si4) GAGCAGAUACUCUUGAUGA
PAN3 (si1) AAAACAAGGUUGCGAGUAA
PAN3 (si2) CGACUUACUUCUAUACAGA
PAN3 (si3) GGUUUGGCAUGUCGAGUUA
PAN3 (si4) GGGCAUAUAUUGUCCAACU
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Figure S3 USP52 depletion destabilizes HIF1A mRNA
(A) Actinomycin D chase experiment in NT siRNA-treated U2OS cells reveals the HIF1A half-life
to be 214 min in a 5 h time course. (B) Actinomycin D chase experiment in USP52-depleted U2OS
cells reveals the H1F1A half-life to be 35 min over a 60 min time course. (C) USP52 depletion
in U2OS cells caused an 80 % reduction in the expression of Renilla luciferase–HIF1A -3′-UTR.
Levels were normalized to firefly luciferase. Results are means+−S.E.M.
Figure S4 Polysome profile of USP52-depleted cells
(A) Real-time RT–PCR analysis of HIF1A mRNA in polysome profile fractions of NT or USP52
siRNA-treated cells. Samples were prepared using a standard polysome profile protocol where
cytosolic lysates were centrifuged at 36 000 rev./min for 3 h using an SW41 Ti swing-out rotor
through a 10–50 % sucrose gradient (prepared at 10 % intervals), and 0.5 ml fractions were
collected for RNA extraction and real-time RT–PCR analysis. (B) A 260 values were taken for each
fraction and plotted. Fraction 13 corresponds to 80S ribosomal RNA, heavier fractions (14–21)
correspond to polysomes and lighter fractions (12 and below) correspond to the untranslated
pool. (C) Fractions were run on an agarose gel and stained with ethidium bromide to enable
RNA to be visualized.
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Figure S5 USP52 is a P-body component
(A) U2OS cells were treated with puromycin or CHX and immunostained with anti-USP52
antibody. USP52-positive foci were increased upon puromycin treatment and decreased upon
CHX treatment confirming USP52 as a P-body component. Scale bars, 30 μm. Cells were
counterstained with DAPI (4′,6-diamidino-2-phenylindole). (B) Quantification of the experiment
shown in Figure 6(A) of the main text. GW182 siRNA reduced the percentage of cells containing
GW182- and USP52-positive P-bodies from approximately 80 % in NT-treated cells (n = 226)
to 20 % in GW182 siRNA-treated cells (n = 185). Results are means+−S.E.M. (C) U2OS cells
were treated with GW182 siRNA and USP52 protein levels were found to be unchanged. Tubulin
was used as a loading control. Molecular masses are indicated in kDa. (D) U2OS cells were
depleted of LSM1 and P-bodies were immunostained with anti-GW182 antibody. P-bodies
were dispersed upon LSM1 treatment. Cells were counterstained with DAPI. Scale bar, 15 μm.
Table S2 Real-time PCR primer and probe sequences
ACTB, β-actin.
Gene Primer/probe Sequence (5′→3′)
USP52 (SYBR) Forward primer ATGAGAAGGGCAGAAAGATGG
USP52 (SYBR) Reverse primer GGGCTATAGAACAGTAAAGGGAG
ACTB (SYBR) Forward primer CCCAGCACAATGAAGATCAAG
ACTB (SYBR) Reverse primer GACTCGTCATACTCCTGCTTG
HIF1A (Solaris) Forward primer TTACCATGCCCCAGATTCAG
HIF1A (Solaris) Reverse primer GGACTATTAGGCTCAGGT
HIF1A (Solaris) Probe GCACTAGACAAAGTTCACC
ACTB (Solaris) Forward primer TGGAGAAAATCTGGCACCAC
ACTB (Solaris) Reverse primer GGTCTCAAACATGATCTGG
ACTB (Solaris) Probe ACCGCGAGAAGATGACC
CA9 (Solaris) Forward primer TGAGTGCTAAGCAGCTCCA
CA9 (Solaris) Reverse primer CCATTCAAAGGCTGCGT
CA9 (Solaris) Probe TGAACTTCCGAGCGACG
HIF2A (Solaris) Forward primer ATGGGACTTACACAGGTGGA
HIF2A (Solaris) Reverse primer GACTCAGGTTCTCACGAATC
HIF2A (Solaris) Probe GCGACCATGAGGAGATT
VEGF (Solaris) Forward primer CATCACCATGCAGATTATGCG
VEGF (Solaris) Reverse primer GCTGTAGGAAGCTCATCTC
VEGF (Solaris) Probe CAAGGCCAGCACATAGGAG
PHD2 (Solaris) Forward primer AGCCCAGTTTGCTGACATTG
PHD2 (Solaris) Reverse primer CCAAACAGTTATTGCGT
PHD2 (Solaris) Probe TATGCTACAAGGTACGC
ERG (Solaris) Forward primer ACACCGTTGGGATGAACT
ERG (Solaris) Reverse primer TACTCCATAGCGTAGGATCTGC
ERG (Solaris) Probe AGAGTTATCGTGCCAGC
CTNNB1 (Solaris) Forward primer TGGCTATTACGACAGACTGC
CTNNB1 (Solaris) Reverse primer AGCCAGTATGATGAGCTTGC
CTNNB1 (Solaris) Probe TTATGGCAACCAAGAAAGC
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Table S3 Sequences of FISH probes
DNA probe Sequence (5′→3′)
HIF1A sense control 1 CTCACAGATGATGGTGACATGATTTACATTTCTGATAATGTGAACAAATACATGGGATTA
HIF1A sense control 2 ATGGATGATGACTTCCAGTTACGTTCCTTCGATCAGTTGTCACCATTAGAAAGCAGTTCC
HIF1A sense control 3 CTATGTAGTTGTGGAAGTTTATGCTAATATTGTGTAACTGATATTAAACCTAAATGTTCT
HIF1A probe (antisense) 1 GAGTGTCTACTACCACTGTACTAAATGTAAAGACTATTACACTTGTTTATGTACCCTAAT
HIF1A probe (antisense) 2 TACCTACTACTGAAGGTCAATGCAAGGAAGCTAGTCAACAGTGGTAATCTTTCGTCAAGG
HIF1A probe (antisense) 3 GATACATCAACACCTTCAAATACGATTATAACACATTGACTATAATTTGGATTTACAAGA
Table S4 List of USP52-interacting proteins identified from MS/MS analysis
Available as an Excel file at http://www.biochemj.org/bj/451/bj4510185add.htm
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